Ronak Chaudhari, MD
Endocrinology, Diabetes & Metabolism · Bowling Green, KYNPI 1861798431
Payments from drug & device makers
Across 1,308 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$15K
- Amgen$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Corcept Therapeutics$1K
- plus $11K from 50 others
What the payments were for
- Consulting fees$1751%
- Speaking & faculty fees$4302%
- Food & beverage$19,48196%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$430
- Prolia$175
How this compares
$34,487 in reported general payments places this provider in the 80th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,310 | $1,650,404 |
| JardianceEmpagliflozin | 1,261 | $1,168,850 |
| TrulicityDulaglutide | 383 | $560,257 |
| FarxigaDapagliflozin Propanediol | 426 | $401,413 |
| MounjaroTirzepatide | 315 | $358,882 |
| Tresiba Flextouch U-200Insulin Degludec | 321 | $310,077 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 162 | $290,752 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 117 | $212,614 |
| KerendiaFinerenone | 127 | $155,890 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 141 | $153,483 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 98 | $116,526 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 633 | $103,133 |
| Humalog Kwikpen U-100Insulin Lispro | 275 | $94,936 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 96 | $94,558 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 185 | $93,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Levemir | $2,015 | $1,766,8911,465 claims |
| Boehringer IngelheimJardiance, Jentadueto Xr, Tradjenta | $1,344 | $1,191,8901,293 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,915 | $942,677788 claims |
| AstraZenecaFarxiga | $270 | $401,413426 claims |
| BayerKerendia | $686 | $155,890127 claims |
| MerckJanumet Xr, Januvia | $300 | $143,338132 claims |
| Radius Health, Inc.Tymlos | $313 | $58,36915 claims |
| AbbVieSynthroid | $576 | $32,034498 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $699 | $22,77717 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $183 | $17,3651,755 claims |
| Johnson & JohnsonInvokana | $167 | $11,28212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Bowling Green
- Javier Duron TaboraBowling Green$11K
- Hamza SheikhBowling Green$7K
- Harold BaysLouisville$12.9M
- Bradley EilermanFlorence$1.9M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Wael EidCovington$509K
- Lyle MyersLexington$434K
- Sathya KrishnasamyLouisville$263K
- Dennis KarounosLexington$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.